Prices are updated after-hours


Sort by: gain open | gain high | gain close | publishing date

symbols : GILD    save search

Second Genome Appoints Joseph Dal Porto, Ph.D., as Chief Scientific Officer
Published: 2022-01-19 (Crawled : 13:00) - biospace.com/
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: -1.62% H: 0.53% C: -1.72%


JYSELECA®▼ (FILGOTINIB) LICENSED FOR THE TREATMENT OF ADULT PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS IN GREAT BRITAIN
Published: 2022-01-18 (Crawled : 01:00) - biospace.com/
GLPG | $56.46 | twitter stocktwits trandingview |
Health Technology
| | O: 1.69% H: 0.0% C: 0.0%
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: -0.65% H: 0.0% C: 0.0%

jyseleca treatment era license
Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022
Published: 2022-01-18 (Crawled : 23:00) - biospace.com/
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: -0.65% H: 0.0% C: 0.0%

financial results ces results
Outlook on the CAR T-cell Therapy Global Market to 2031 - by Product Type, Indications, End-user and Region
Published: 2022-01-14 (Crawled : 14:00) - prnewswire.com
NVSEF | News | $88.6 | twitter stocktwits trandingview |
Health Technology
| | O: 1.26% H: 0.0% C: 0.0%
SRNE | $4.45 | twitter stocktwits trandingview |
Health Technology
| | O: -5.96% H: 0.0% C: 0.0%
NVS | News | $88.91 | twitter stocktwits trandingview |
Health Technology
| | O: 0.02% H: 0.0% C: 0.0%
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: -0.32% H: 0.0% C: 0.0%
BLUE | $6.93 | twitter stocktwits trandingview |
Health Technology
| | O: -0.57% H: 0.0% C: 0.0%
JNJ | News | $167.27 | twitter stocktwits trandingview |
Health Technology
| | O: -0.53% H: 0.0% C: 0.0%

era cel therapy t-cell
BioSpace Movers & Shakers, Jan. 14
Published: 2022-01-14 (Crawled : 13:30) - biospace.com/
JNJ | News | $167.27 | twitter stocktwits trandingview |
Health Technology
| | O: -0.53% H: 0.0% C: 0.0%
GSK | News | $45.14 | twitter stocktwits trandingview |
Health Technology
| | O: -0.35% H: 0.0% C: 0.0%
LLY | News | $246.46 | twitter stocktwits trandingview |
Health Technology
| | O: -1.46% H: 0.0% C: 0.0%
AMRX | $4.4 | twitter stocktwits trandingview |
Health Technology
| | O: -1.71% H: 0.0% C: 0.0%
MRTX | News | $118.34 | twitter stocktwits trandingview |
Health Technology
| | O: -2.14% H: 0.0% C: 0.0%
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: -0.32% H: 0.0% C: 0.0%
GLAXF | News | $22.8 | twitter stocktwits trandingview |
Health Technology
| | O: -1.67% H: 3.62% C: 3.62%
PPG | $159.7 | twitter stocktwits trandingview |
Process Industries
| | O: -2.07% H: 0.0% C: 0.0%
AMGN | $233.73 | twitter stocktwits trandingview |
Health Technology
| | O: -0.53% H: 0.0% C: 0.0%
PHAT | $15.0 | twitter stocktwits trandingview |
Health Technology
| | O: -3.08% H: 0.0% C: 0.0%

space spac
ReCode Therapeutics Appoints Shehnaaz Suliman, M.D., MBA, M.Phil., as Chief Executive Officer
Published: 2022-01-10 (Crawled : 20:00) - biospace.com/
ARVL | News | $5.95 | twitter stocktwits trandingview |
Manufacturing
| | O: 1.88% H: 0.0% C: 0.0%
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: 1.02% H: 0.36% C: 0.14%


Gilead Announces Clinical Trial Collaborations With Merck to Evaluate Trodelvy® in Combination With KEYTRUDA® in First-Line Metastatic Non-Small Cell Lung Cancer
Published: 2022-01-10 (Crawled : 14:30) - biospace.com/
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: 1.02% H: 0.36% C: 0.14%


Everest Medicines Will Participate in a Clinical Trial with Gilead and MSD to Evaluate Trodelvy® in Combination with KEYTRUDA® (pembrolizumab) in First-Line Metastatic Non-Small Cell Lung Cancer
Published: 2022-01-10 (Crawled : 14:30) - biospace.com/
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: 1.02% H: 0.36% C: 0.14%


Xilio Therapeutics Appoints Yuan Xu, Ph.D., to its Board of Directors
Published: 2022-01-06 (Crawled : 14:00) - biospace.com/
FATE | $38.3 | twitter stocktwits trandingview |
Health Technology
| | O: -0.56% H: 2.27% C: -4.25%
AKRO | $20.01 | twitter stocktwits trandingview |
Health Technology
| | O: -0.35% H: 4.23% C: 3.03%
GLAXF | News | $22.8 | twitter stocktwits trandingview |
Health Technology
| | O: -2.58% H: 1.2% C: 0.05%
LEGN | $39.19 | twitter stocktwits trandingview |
Health Technology
| | O: -7.55% H: 3.65% C: 3.07%
AMGN | $233.73 | twitter stocktwits trandingview |
Health Technology
| | O: -0.64% H: 0.67% C: 0.01%
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: -0.96% H: 0.58% C: -0.12%
XLO | $13.93 | twitter stocktwits trandingview |
Professional, Scientific, and T...
| | O: 0.33% H: 5.33% C: -4.47%
GSK | News | $45.14 | twitter stocktwits trandingview |
Health Technology
| | O: -0.96% H: 0.0% C: 0.0%

era therapeutics
Everest Medicines Announces Taiwan FDA Has Accepted New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer
Published: 2022-01-04 (Crawled : 01:00) - prnewswire.com
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: 0.4% H: 0.0% C: 0.0%

new drug fda application ces drug cancer negative breast cancer
Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns
Published: 2021-12-22 (Crawled : 06:00) - biospace.com/
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: -0.35% H: 1.22% C: 1.17%

clinical hold treatment ces hiv
HPTN Studies Inform FDA’s Approval of ViiV Healthcare’s Long-Acting Cabotegravir Injections for HIV Prevention
Published: 2021-12-21 (Crawled : 22:00) - biospace.com/
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.17% C: -0.87%

fda health thc approval injection hiv
European Commission Expands Indication for Veklury (Remdesivir) for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression
Published: 2021-12-21 (Crawled : 11:00) - biospace.com/
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: 0.0% H: 0.17% C: -0.87%

covid-19 treatment europe risk oxygen covid disease
Second Genome Granted U.S. Patent for Proteins for the Treatment or Prevention of Epithelial Barrier Function Disorders
Published: 2021-12-20 (Crawled : 13:00) - biospace.com/
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: -0.3% H: 0.72% C: 0.65%

treatment order patent granted
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
Published: 2021-12-14 (Crawled : 01:00) - biospace.com/
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: -0.37% H: 0.0% C: 0.0%

new drug application ces drug cancer negative breast cancer
Everest Medicines Announces the Acceptance of a New Drug Application for Sacituzumab Govitecan in Second-Line Metastatic Triple-Negative Breast Cancer in South Korea
Published: 2021-12-15 (Crawled : 01:00) - prnewswire.com
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: 0.99% H: 1.23% C: 0.94%

new drug application ces drug cancer negative breast cancer
Yescarta® ZUMA-12 Study Demonstrates 78% Complete Response Rate as Part of First-Line Treatment in Newly Diagnosed High-Risk Large B-Cell Lymphoma
Published: 2021-12-13 (Crawled : 22:00) - biospace.com/
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: -0.09% H: 0.0% C: 0.0%

zuma-12 yescarta treatment risk
Trodelvy® Demonstrates Clinical Benefit for Black Patients Consistent with Full Metastatic Triple-Negative Breast Cancer Population in ASCENT Study
Published: 2021-12-10 (Crawled : 15:00) - biospace.com/
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: -0.17% H: 0.0% C: 0.0%

trodelvy cancer negative breast cancer
Global HIV-1 Market and Epidemiology Overview 2018-2030 with Insights Into Marketed & Emerging Drugs from Merck Sharp & Dohme, Gilead Sciences, and ViiV Healthcare
Published: 2021-12-08 (Crawled : 11:00) - prnewswire.com
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: 0.72% H: 0.82% C: -0.29%
THTX | $2.97 | twitter stocktwits trandingview |
Health Technology
| | O: -2.48% H: 4.46% C: 3.5%
SNY | News 3 d | $52.31 | twitter stocktwits trandingview |
Health Technology
| | O: 1.54% H: 0.0% C: 0.0%
SNYNF | News 3 d | $105.0 | twitter stocktwits trandingview |
Health Technology
| | O: -2.14% H: 0.34% C: 0.34%

thc drug hiv
Actemra/RoActemra approved by the European Commission to treat patients with severe COVID-19
Published: 2021-12-07 (Crawled : 10:00) - globenewswire.com
GILD | $67.81 | twitter stocktwits trandingview |
Health Technology
| | O: -0.14% H: 0.0% C: 0.0%

europe covid
Your saved searches


Save your searches and get alerts when important news are released.

Mentioned Today
COTY | News | $8.64 | twitter stocktwits trandingview |
Consumer Non-Durables

DXR | News | $11.16 | twitter stocktwits trandingview |
Health Technology

FCFS | News | $73.31 | twitter stocktwits trandingview |
Finance

INCY | News | $74.76 | twitter stocktwits trandingview |
Health Technology

KRP | News | $14.73 | twitter stocktwits trandingview |
Miscellaneous

LLY | News | $246.46 | twitter stocktwits trandingview |
Health Technology

OVLY | News | $17.6 | twitter stocktwits trandingview |
Finance